Developed as part of Astellas Pharma’s global expansion strategy, this aseptic manufacturing facility required highly specialised building services infrastructure to support the production of innovative antibody drugs within a rigorously controlled pharmaceutical environment. The project demanded technically complex MEP systems capable of meeting stringent GMP, environmental, and operational performance standards across sterile manufacturing and pharma-grade storage areas.
